Thera-SAbDab

LENZILUMAB

>   Structural Summary
TherapeuticLenzilumab
TargetCSF2
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-I/II
Estimated Status (June '19)Active
Recorded Developmental TechnologyHumaneering Technology
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedHumanigen, KaloBios Pharmaceuticals
Conditions Approvedna
Conditions ActiveDrug hypersensitivity, Chronic myelomonocytic leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma, Solid tumours
Conditions DiscontinuedAsthma, Rheumatoid arthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]